#USA #San Diego #Class Action #SEC violations #Hims & Hers

Hims & Hers Health Class Action Notification

Investors who have experienced considerable losses from Hims & Hers Health, Inc. (NYSE: HIMS) securities during the specified class period from August 4, 2025, to July 29, 2026, are being advised to take action. The law firm Robbins Geller Rudman & Dowd LLP has initiated a process that allows eligible investors to apply for lead plaintiff status in the ongoing class action lawsuit against Hims & Hers. The deadline for this application is set for November 2, 2026, which is fast approaching.

Background of the Case

The case, titled Velanki v. Hims & Hers Health, Inc., filed in the Northern District of California, raises significant allegations against the company and its executives, including breaches of the Securities Exchange Act of 1934. The lawsuit claims that during the class period, Hims & Hers made numerous misleading statements and omitted crucial information regarding their business practices, particularly related to financial transactions and privacy violations.

Key Allegations Against Hims & Hers

Hims & Hers, a health and wellness platform aimed at connecting consumers to licensed healthcare professionals, is accused of serious misconduct. The core allegations include:
1. Disclosure Failures: Hims & Hers purportedly shared sensitive consumer health information with third-party advertising entities without clear consent from the users. This creates a significant breach of trust and privacy expectations.
2. Misleading Practices: Despite assurances that consumers would have proper consultations before any prescriptions were charged, the company allegedly billed clients shortly after they submitted intake forms. This raises concerns about the ethical handling of client interactions and financial practices.
3. Regulatory Scrutiny: The described practices have attracted scrutiny from regulatory bodies, leading to potential fines and legal consequences, thus solidifying the case that Hims & Hers' optimistic portrayals were misleading and lacked basis.

Impact on Investors

In response to these allegations, on July 29, 2026, the Federal Trade Commission filed a lawsuit against Hims & Hers, emphasizing unauthorized sharing of consumer health data and deceptive advertising practices. Following this announcement, the market reacted negatively, resulting in a nearly 15% decline in the stock price of Hims & Hers.

The Role of a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased shares within the specified class period can pursue lead plaintiff designation. A lead plaintiff is typically the one with the most significant financial interest that is common with the claims of the group. They serve to represent the class and direct litigation strategy, including selecting a law firm, in this case, Robbins Geller.

It is critical to note that being designated as a lead plaintiff does not affect an investor's potential recovery; all eligible members can seek restitution regardless of their role in plaintiffs' leadership.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is celebrated for its proficiency in securities fraud litigation, recording remarkable success in obtaining settlements for investors. In 2025 alone, they reclaimed over $916 million across various cases, ranking them at the top of the ISS Securities Class Action Services Top 50 Report.

If you are an affected investor, it is advisable to evaluate your position carefully. For more information on how to proceed, visit their dedicated case page or contact their offices. The stakes are high; securing your role as lead plaintiff may influence your ability to reclaim losses suffered.